Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Use of phage therapy to treat long-standing, persistent, or chronic bacterial infections.

Abedon ST.

Adv Drug Deliv Rev. 2019 May;145:18-39. doi: 10.1016/j.addr.2018.06.018. Epub 2018 Jul 3. Review.

PMID:
31708017
2.

Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.

Dąbrowska K, Abedon ST.

Microbiol Mol Biol Rev. 2019 Oct 30;83(4). pii: e00012-19. doi: 10.1128/MMBR.00012-19. Print 2019 Nov 20. Review.

PMID:
31666296
3.
4.

Phage-Antibiotic Combination Treatments: Antagonistic Impacts of Antibiotics on the Pharmacodynamics of Phage Therapy?

Abedon ST.

Antibiotics (Basel). 2019 Oct 11;8(4). pii: E182. doi: 10.3390/antibiotics8040182. Review.

5.

Commentary: A Host-Produced Quorum-Sensing Autoinducer Controls a Phage Lysis-Lysogeny Decision.

Igler C, Abedon ST.

Front Microbiol. 2019 Jun 3;10:1171. doi: 10.3389/fmicb.2019.01171. eCollection 2019. No abstract available.

6.

Fighting Fire with Fire: Phage Potential for the Treatment of E. coli O157 Infection.

Howard-Varona C, Vik DR, Solonenko NE, Li YF, Gazitua MC, Chittick L, Samiec JK, Jensen AE, Anderson P, Howard-Varona A, Kinkhabwala AA, Abedon ST, Sullivan MB.

Antibiotics (Basel). 2018 Nov 16;7(4). pii: E101. doi: 10.3390/antibiotics7040101.

7.

Phage Therapy: Various Perspectives on How to Improve the Art.

Abedon ST.

Methods Mol Biol. 2018;1734:113-127. doi: 10.1007/978-1-4939-7604-1_11.

PMID:
29288451
8.

Basic Phage Mathematics.

Abedon ST, Katsaounis TI.

Methods Mol Biol. 2018;1681:3-30. doi: 10.1007/978-1-4939-7343-9_1. Review.

PMID:
29134583
9.

Bacteriophage Clinical Use as Antibacterial "Drugs": Utility and Precedent.

Abedon ST.

Microbiol Spectr. 2017 Aug;5(4). doi: 10.1128/microbiolspec.BAD-0003-2016. Review.

PMID:
28840811
10.

Active bacteriophage biocontrol and therapy on sub-millimeter scales towards removal of unwanted bacteria from foods and microbiomes.

Abedon ST.

AIMS Microbiol. 2017 Aug 4;3(3):649-688. doi: 10.3934/microbiol.2017.3.649. eCollection 2017.

11.

Editorial: Phage Therapy: Past, Present and Future.

Abedon ST, García P, Mullany P, Aminov R.

Front Microbiol. 2017 Jun 15;8:981. doi: 10.3389/fmicb.2017.00981. eCollection 2017. No abstract available.

12.

An online phage therapy bibliography: separating under-indexed wheat from overly indexed chaff.

Alves DR, Abedon ST.

AIMS Microbiol. 2017 Jun 27;3(3):525-528. doi: 10.3934/microbiol.2017.3.525. eCollection 2017. No abstract available.

13.

Commentary: Communication between Viruses Guides Lysis-Lysogeny Decisions.

Abedon ST.

Front Microbiol. 2017 May 31;8:983. doi: 10.3389/fmicb.2017.00983. eCollection 2017. No abstract available.

14.

Information Phage Therapy Research Should Report.

Abedon ST.

Pharmaceuticals (Basel). 2017 Apr 30;10(2). pii: E43. doi: 10.3390/ph10020043.

15.

Phage "delay" towards enhancing bacterial escape from biofilms: a more comprehensive way of viewing resistance to bacteriophages.

Abedon ST.

AIMS Microbiol. 2017 Mar 31;3(2):186-226. doi: 10.3934/microbiol.2017.2.186. eCollection 2017.

16.

Lysogeny in nature: mechanisms, impact and ecology of temperate phages.

Howard-Varona C, Hargreaves KR, Abedon ST, Sullivan MB.

ISME J. 2017 Jul;11(7):1511-1520. doi: 10.1038/ismej.2017.16. Epub 2017 Mar 14.

17.

Phage therapy dosing: The problem(s) with multiplicity of infection (MOI).

Abedon ST.

Bacteriophage. 2016 Aug 11;6(3):e1220348. eCollection 2016 Jul-Sep.

18.

Commentary: Phage Therapy of Staphylococcal Chronic Osteomyelitis in Experimental Animal Model.

Abedon ST.

Front Microbiol. 2016 Aug 10;7:1251. doi: 10.3389/fmicb.2016.01251. eCollection 2016. No abstract available.

19.

Diversity of phage infection types and associated terminology: the problem with 'Lytic or lysogenic'.

Hobbs Z, Abedon ST.

FEMS Microbiol Lett. 2016 Apr;363(7). pii: fnw047. doi: 10.1093/femsle/fnw047. Epub 2016 Feb 29. Review.

PMID:
26925588
20.

Bacteriophage exploitation of bacterial biofilms: phage preference for less mature targets?

Abedon ST.

FEMS Microbiol Lett. 2016 Feb;363(3). pii: fnv246. doi: 10.1093/femsle/fnv246. Epub 2016 Jan 6.

PMID:
26738755
21.

Phage therapy of pulmonary infections.

Abedon ST.

Bacteriophage. 2015 Apr 18;5(1):e1020260. eCollection 2015 Jan-Mar. Review.

22.

Ecology of Anti-Biofilm Agents II: Bacteriophage Exploitation and Biocontrol of Biofilm Bacteria.

Abedon ST.

Pharmaceuticals (Basel). 2015 Sep 9;8(3):559-89. doi: 10.3390/ph8030559. Review.

23.

Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages.

Abedon ST.

Pharmaceuticals (Basel). 2015 Sep 9;8(3):525-58. doi: 10.3390/ph8030525. Review.

24.

Re-establishing a place for phage therapy in western medicine.

Kutter EM, Kuhl SJ, Abedon ST.

Future Microbiol. 2015;10(5):685-8. doi: 10.2217/fmb.15.28. Review. No abstract available.

25.

Bacteriophage secondary infection.

Abedon ST.

Virol Sin. 2015 Feb;30(1):3-10. doi: 10.1007/s12250-014-3547-2. Epub 2015 Jan 13. Review.

PMID:
25595214
26.

Virus ecology and disturbances: impact of environmental disruption on the viruses of microorganisms.

Allen HK, Abedon ST.

Front Microbiol. 2014 Dec 12;5:700. doi: 10.3389/fmicb.2014.00700. eCollection 2014. No abstract available.

27.

Bacteriophages and their enzymes in biofilm control.

Chan BK, Abedon ST.

Curr Pharm Des. 2015;21(1):85-99. Review.

PMID:
25189866
28.

Phage therapy: eco-physiological pharmacology.

Abedon ST.

Scientifica (Cairo). 2014;2014:581639. doi: 10.1155/2014/581639. Epub 2014 May 20. Review.

29.

That's disturbing! An exploration of the bacteriophage biology of change.

Allen HK, Abedon ST.

Front Microbiol. 2013 Nov 14;4:295. doi: 10.3389/fmicb.2013.00295. eCollection 2013. No abstract available.

30.

Phage cocktails and the future of phage therapy.

Chan BK, Abedon ST, Loc-Carrillo C.

Future Microbiol. 2013 Jun;8(6):769-83. doi: 10.2217/fmb.13.47. Review.

31.

Archaeal viruses, not archaeal phages: an archaeological dig.

Abedon ST, Murray KL.

Archaea. 2013;2013:251245. doi: 10.1155/2013/251245. Epub 2013 Apr 7. Review.

32.

Are archaeons incapable of being parasites or have we simply failed to notice?

Abedon ST.

Bioessays. 2013 Jun;35(6):501. doi: 10.1002/bies.201300032. Epub 2013 Apr 10. No abstract available.

PMID:
23575903
33.

Thinking about microcolonies as phage targets.

Abedon ST.

Bacteriophage. 2012 Jul 1;2(3):200-204.

34.
35.

Bacterial 'immunity' against bacteriophages.

Abedon ST.

Bacteriophage. 2012 Jan 1;2(1):50-54.

36.

Pros and cons of phage therapy.

Loc-Carrillo C, Abedon ST.

Bacteriophage. 2011 Mar;1(2):111-114.

37.

Phage treatment of human infections.

Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM.

Bacteriophage. 2011 Mar;1(2):66-85.

38.

Phage therapy pharmacology phage cocktails.

Chan BK, Abedon ST.

Adv Appl Microbiol. 2012;78:1-23. doi: 10.1016/B978-0-12-394805-2.00001-4.

PMID:
22305091
39.

Smaller fleas: viruses of microorganisms.

Hyman P, Abedon ST.

Scientifica (Cairo). 2012;2012:734023. doi: 10.6064/2012/734023. Epub 2012 Jun 26. Review.

40.

Facilitation of CRISPR adaptation.

Abedon ST.

Bacteriophage. 2011 May;1(3):179-181. Epub 2011 May 1.

41.

Bacteriophage prehistory: Is or is not Hankin, 1896, a phage reference?

Abedon ST, Thomas-Abedon C, Thomas A, Mazure H.

Bacteriophage. 2011 May;1(3):174-178. Epub 2011 May 1.

42.

Envisaging bacteria as phage targets.

Abedon ST.

Bacteriophage. 2011 Jul 1;1(4):228-230.

43.

Lysis from without.

Abedon ST.

Bacteriophage. 2011 Jan;1(1):46-49.

44.

Bacteriophage host range and bacterial resistance.

Hyman P, Abedon ST.

Adv Appl Microbiol. 2010;70:217-48. doi: 10.1016/S0065-2164(10)70007-1. Epub 2010 Mar 6. Review.

PMID:
20359459
45.

Kinetics of phage-mediated biocontrol of bacteria.

Abedon ST.

Foodborne Pathog Dis. 2009 Sep;6(7):807-15. doi: 10.1089/fpd.2008.0242. Review.

PMID:
19459758
46.

Phage evolution and ecology.

Abedon ST.

Adv Appl Microbiol. 2009;67:1-45. doi: 10.1016/S0065-2164(08)01001-0. Review.

PMID:
19245935
47.

Phage therapy in clinical practice: treatment of human infections.

Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST.

Curr Pharm Biotechnol. 2010 Jan;11(1):69-86. Review.

PMID:
20214609
48.

Phage therapy pharmacology.

Abedon ST, Thomas-Abedon C.

Curr Pharm Biotechnol. 2010 Jan;11(1):28-47. Review.

PMID:
20214606
49.

The 'nuts and bolts' of phage therapy.

Abedon ST.

Curr Pharm Biotechnol. 2010 Jan;11(1):1. No abstract available.

PMID:
20214603
50.

Practical methods for determining phage growth parameters.

Hyman P, Abedon ST.

Methods Mol Biol. 2009;501:175-202. doi: 10.1007/978-1-60327-164-6_18.

PMID:
19066822

Supplemental Content

Loading ...
Support Center